Industry First: VistaJet Abolishes Positioning Fees Globally
To free its Program customers from expensive ferry fees, company will never charge them for positioning an aircraft anywhere in the world.
- Positioning fees can cost customers an additional five-figures on each flight.
- Other business aviation companies charge for positioning fees when leaving their limited service areas.
- The announcement is a result of VistaJet's $2.5bn investment in its global fleet and proprietary backend operations technology.
- Company took on 15 new business jets in 2016, taking the total fleet to over 70, to offer one-way pricing around the globe.
- Follows 100,000th VistaJet flight record.
LONDON, May 19, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global aviation company, announced today that it has abolished hourly ferry flight fees for new Program customers globally. Uniquely in the industry, the commitment applies no matter where in the world a customer is flying to or from. The move signals a significant commitment to VistaJet's mission to be the first operator to offer a truly global service. Its customers now have complete freedom when booking, without bearing the burden of paying a ferry flight hourly rate for an aircraft to return to a home base or service area, and enjoying truly transparent pricing.
Photos accompanying this announcement are available at
Positioning fees have traditionally been a frustrating and unexpected cost for business aviation clients. Currently, most companies in the sector make their customers pay for the cost of returning the empty plane to its home airport or service area after a flight is completed. Depending on location, this can add tens of thousands to the overall cost of a flight. For example, if a customer stepped onboard a London based aircraft towards Australia, the cost of returning the aircraft to its home base could add more than $100,000 to the overall cost of the journey.
The revolutionary new offering has been made possible by the $2.5bn investment the company has made to grow its fleet to a global scale, as well as its effort to establish a global customer base through its 10 sales offices around the globe. The company's unique business model, built on removing the notion of a home base for its aircraft, means customers only pay for the time they are in the air: when a VistaJet Program customer books a flight, VistaJet will simply move the nearest plane to pick them up.
Unlike business jet charter, VistaJet owns every one of the over 70 silver and red aircraft in its fleet, so customers know what will greet them on the tarmac anytime, anywhere in the world. The company has invested in an industry leading operations centre in the European country of Malta, and created an innovative infrastructure with the capacity to manage global flights 24 hours a day, 365 days a year. It has also established offices on 5 continents, managing flights to over 1,600 airports in 187 countries to date.
Chairman and Founder Thomas Flohr said:
"When you call a taxi, you don't worry about paying for its journey to you. Today's entrepreneur or business executive will be flying to America one week, Asia or South America the next, and Europe in between, so it's become critical to offer them a truly global service. The sustained investment we've made for the past 13 years has been calculated to ensure we can offer our customers something completely ground-breaking: one way pricing around the globe.
At VistaJet, we challenge ourselves every day to offer the best experience in the industry. So along with knowing that our customers will only pay for the time they are in the air, when they fly with us they know that they will receive the very best service, with everything tailored to their specific needs."
VistaJet is the first and only global aviation company. On its fleet of silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries worldwide. Founded in 2004 by Thomas Flohr, the company pioneered an innovative business model where customers pay only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet's signature Program service offers customers a bespoke subscription of flight hours on its fleet of mid and long range jets, to fly them anywhere and at any time.
More VistaJet information and news at vistajet.com.
Information Jennifer Tyler VistaJet International T: +44 203 617 3077 M: +44 7834 335505 firstname.lastname@example.org James Leviton Finsbury +44 207 251 3851 VistaJet@finsbury.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VistaJet Ltd via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00 | Pressmeddelande
AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech
At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58 | Pressmeddelande
LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service. As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al
Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00 | Pressmeddelande
Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00 | Pressmeddelande
Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea
Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00 | Pressmeddelande
Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23 | Pressmeddelande
DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum